Skip to main content
Top

21-07-2016 | Endocrine cancers | Book chapter | Article

15. Management of Patients with Metastatic Medullary Thyroid Carcinoma: The Role for Systemic Therapy

Author: Gilbert G. Fareau

Publisher: Springer International Publishing

Abstract

Medullary thyroid carcinoma (MTC) is an uncommon neuroendocrine malignancy that arises from the parafollicular C-cells of the thyroid gland and which frequency metastasizes to local and distant sites. Although often slowly growing, progressive metastatic disease is the cause of death in most patients with advanced MTC and the prognosis typically falls between that of differentiated follicular epithelial and anaplastic forms of thyroid cancer. In the past, effective treatment options were lacking for patients with advanced MTC, since only minimal response rates were seen with the use of traditional cytotoxic agents. However, recent elucidation of key intracellular signaling cascades that contribute to tumorigenesis has fostered development of small molecule kinase inhibitors that offer effective therapeutic options for patients with progressive disease. While these novel agents have had a profound effect on the management of advanced MTC, standardization of practice is challenged by the relative rarity of this tumor and the infrequent need for systemic therapy. This chapter outlines a suggested approach to the use of systemic therapy in progressive metastatic MTC.
Literature
1.
Jadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diab Endocrinol. 2016;4:64–71.CrossRef
2.
Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–48.CrossRefPubMed
3.
Schlumberger M, Hastholt L, Dralle H, Jarzab H, Pacini F, Smit JWA. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1:5–14.CrossRefPubMedPubMedCentral
4.
Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134–42.CrossRefPubMed
5.
Links TP, Verbeek HH, Hofstra RM, Plukker JT. Eur J Endocrinol. 2015;172:241–51.CrossRef
6.
Giraudet AL, Ghulzan AA, Auperin A, Lenoulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239–46.CrossRef
7.
Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, GTE study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077–84.
8.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
9.
Wells SA, Asa SL, Henning D, Rossella E, Evans DB, Gagel RF, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma: the American thyroid association guidelines task force on medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRefPubMedPubMedCentral
10.
NCCN. NCCN clinical practice guidelines in oncology: thyroid carcinoma (version 2.2015). Fort Washington, PA: National Comprehensive Cancer Network.
11.
Links TP, Verbeek HH, Hofstra RM, Plukker JT. Progressive metastatic medullary thyroid carcinoma: first- and second-line therapies. Eur J Endocrinol. 2015;172:241–51.CrossRef
12.
Maxwell JE, Sherman SK, O’Dorisio TM, Howe JR. Medical management of metastatic medullary thyroid cancer. Cancer. 2014;120:3287–301.CrossRefPubMedPubMedCentral
13.
Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab. 2009;91:1493–9.CrossRef
14.
Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767–72.CrossRefPubMedPubMedCentral
15.
Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2664–71.CrossRefPubMedPubMedCentral
16.
Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134–41.CrossRefPubMed
17.
AstraZeneca. Caprelsa REMS program [internet]. 2013 [updated 2013 Dec; cited 2016 Feb]. Available from http://​www.​caprelsarems.​com/​.
18.
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660–6.CrossRefPubMedPubMedCentral
19.
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.CrossRefPubMedPubMedCentral
20.
Sherman S. Short oral communication 51: The impact of RET and RAS mutation status on overall survival in the exam trial, a phase 3 study of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Presented at 15th international thyroid congress and 85th annual meeting of the American thyroid association, 18–23 Oct 2015, Lake Buena Vista, Florida.
21.
Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. Eur J Endocrinol. 2011;165:315–22.CrossRefPubMed
22.
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Jiachoa Liang, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323–30.CrossRefPubMedPubMedCentral
23.
Capdevila J, Iglesias L, Halperin I, Segura A, Martinez J, Angeles Vaz A, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 2012;19:209–16.CrossRefPubMed
24.
Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014;99:1687–93.CrossRefPubMedPubMedCentral
25.
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2015;22(1):44–53.CrossRefPubMed
26.
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–8.CrossRefPubMedPubMedCentral
27.
Cohen EE, Needles BM, Cullen KJ, Wong S, Wade J, Ivy P, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol. 2008;26:6025.
28.
Ravaud A, de la Fouchardiere C, Courbon F, Asselineau J, Klein M, Nicoli-Sire P, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol (Meet Abstr). 2008;26(5):6058.
29.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–55.
30.
Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 191–205.
31.
Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol. 2011;29(25):3450–6.CrossRefPubMed
32.
Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metabolism. 2009;23:713–22.CrossRef
33.
Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98:31–42.CrossRefPubMed
34.
Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4(1):22–32.CrossRefPubMed
35.
Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res. 2011;2011:1–9.CrossRef
36.
Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther. 2013;30:945–66.CrossRefPubMedPubMedCentral
37.
Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5):807–15.CrossRefPubMed
38.
Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011;37:75–88.CrossRefPubMed
39.
NCI. CTCAE. Available from http://​evs.​nci.​nih.​gov/​ftp1/​CTCAE/​CTCAE_​4.​03_​2010-06-14_​QuickReference_​5x7.​pdf.​ Updated 2010 June; cited 2016 Feb.